Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lixisenatide vs Exenatide in Type 2 Diabetes
NCT00707031Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2008
- Primary completion
- Nov 2010
- Modality
- Peptides
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of lixisenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 24 weeks. Started Jun 2008; status: completed.
02
Drugs
lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00707031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00707031.